4th International Consensus Conference: Primary Systemic Treatment in the Management of Operable Breast Cancer: toward the rapid assessment of therapy efficacy
"To clarify the role and setting for P[rimary] S[ystemic] T[herapy], during the Fourth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer held from the 26th to 28th of September 2010 in Cremona (Italy), a faculty comprising experts in the areas of medical oncology...
Gespeichert in:
| Körperschaft: | |
|---|---|
| Format: | Tagungsbericht Buch |
| Sprache: | English |
| Veröffentlicht: |
Cary, NC
Oxford Univ. Press
2011
|
| Schriftenreihe: | Journal of the National Cancer Institute
Monographs ; 43 |
| Schlagworte: | |
| Online-Zugang: | Inhaltsverzeichnis |
| Zusammenfassung: | "To clarify the role and setting for P[rimary] S[ystemic] T[herapy], during the Fourth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer held from the 26th to 28th of September 2010 in Cremona (Italy), a faculty comprising experts in the areas of medical oncology, breast surgery, molecular biology, pathology, radiodiagnostics, and radiotherapy provided an overview of recent available data from the most relevant studies and prospective clinical trials of PST in patients with operable breast cancer. At the conclusion of the congress and in the discussion, the panel of experts formulated a declaration of consensus regarding some key issues on the use of PST either in routine practice or clinical research." |
| Beschreibung: | Includes bibliographical references The treatment of individual patients is more than a trial -- Strategies to translate preclinical information to breast cancer patient benefit -- The value of genomic analysis of breast cancer in drug development -- Biomarkers predicting clinical benefit: fact or fiction? -- Molecular oncology and the neoadjuvant setting: the perfect blend for treatment personalization and clinical trial design -- Assessing early therapeutic response to bevacizumab in primary breast cancer using magnetic resonance imaging and gene expression profiles -- Tissue and soluble biomarkers in breast cancer and their applications: ready to use? -- kConFab: a familial breast cancer consortium facilitating research and translational oncology -- The HER2 world: better treatment selection for better outcome -- The pathologic complete response open question in primary therapy -- Surrogate markers for targeted therapy-based treatment activity and efficacy -- Mechanisms of resistance to HER2 target therapy -- Predictive immunohistochemical biomarkers in the context of neoadjuvant therapy for breast cancer -- Dynamic contrast-enhanced magnetic resonance imaging and blood oxygenation level-dependent magnetic resonance imaging for the assessment of changes in tumor biology with treatment -- The triple-negative subtype: new ideas for the poorest prognosis breast cancer -- Positron emission tomography and neoadjuvant therapy of breast cancer -- Neoadjuvant chemotherapy and targeted therapies: a promising strategy -- Endocrine therapy, new biologicals, and new study designs for presurgical studies in breast cancer -- Gene profiling assay and application: the predictive role in primary therapy -- New omics information for clinical trial utility in the primary setting -- Bridging the gap between translational research and clinical application -- Neoadjuvant chemotherapy: early response as a guide for further treatment: clinical, radiological, and biological -- Intermediate endpoints of primary systemic therapy in breast cancer patients -- International expert consensus on primary systemic therapy in the management of early breast cancer: highlights of the Fourth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2010) |
| Beschreibung: | V S., S. 53 - 152 Ill., graph. Darst |
Internformat
MARC
| LEADER | 00000nam a2200000 cb4500 | ||
|---|---|---|---|
| 001 | BV039720476 | ||
| 003 | DE-604 | ||
| 005 | 20111130 | ||
| 007 | t | ||
| 008 | 111123s2011 ad|| |||| 10||| eng d | ||
| 035 | |a (OCoLC)759862263 | ||
| 035 | |a (DE-599)BVBBV039720476 | ||
| 040 | |a DE-604 |b ger |e rakwb | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-29 |a DE-355 |a DE-19 |a DE-12 | ||
| 111 | 2 | |a International Consensus Conference: Primary Systemic Treatment in the Management of Operable Breast Cancer |n 4 |d 2010 |c Cremona |j Verfasser |0 (DE-588)16330833-0 |4 aut | |
| 245 | 1 | 0 | |a 4th International Consensus Conference: Primary Systemic Treatment in the Management of Operable Breast Cancer |b toward the rapid assessment of therapy efficacy |c sponsored by U.O. Multidisciplinare di Patologia Mammaria, Laboratorio di Oncologia Molecolare Senologica, A.O. "Istituti Ospitalieri di Cremona" |
| 246 | 1 | 3 | |a Fourth International Consensus Conference: Primary Systemic Treatment in the Management of Operable Breast Cancer |
| 264 | 1 | |a Cary, NC |b Oxford Univ. Press |c 2011 | |
| 300 | |a V S., S. 53 - 152 |b Ill., graph. Darst | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 490 | 1 | |a Journal of the National Cancer Institute : Monographs |v 43 | |
| 500 | |a Includes bibliographical references | ||
| 500 | |a The treatment of individual patients is more than a trial -- Strategies to translate preclinical information to breast cancer patient benefit -- The value of genomic analysis of breast cancer in drug development -- Biomarkers predicting clinical benefit: fact or fiction? -- Molecular oncology and the neoadjuvant setting: the perfect blend for treatment personalization and clinical trial design -- Assessing early therapeutic response to bevacizumab in primary breast cancer using magnetic resonance imaging and gene expression profiles -- Tissue and soluble biomarkers in breast cancer and their applications: ready to use? -- kConFab: a familial breast cancer consortium facilitating research and translational oncology -- The HER2 world: better treatment selection for better outcome -- The pathologic complete response open question in primary therapy -- Surrogate markers for targeted therapy-based treatment activity and efficacy -- Mechanisms of resistance to HER2 target therapy -- | ||
| 500 | |a Predictive immunohistochemical biomarkers in the context of neoadjuvant therapy for breast cancer -- Dynamic contrast-enhanced magnetic resonance imaging and blood oxygenation level-dependent magnetic resonance imaging for the assessment of changes in tumor biology with treatment -- The triple-negative subtype: new ideas for the poorest prognosis breast cancer -- Positron emission tomography and neoadjuvant therapy of breast cancer -- Neoadjuvant chemotherapy and targeted therapies: a promising strategy -- Endocrine therapy, new biologicals, and new study designs for presurgical studies in breast cancer -- Gene profiling assay and application: the predictive role in primary therapy -- New omics information for clinical trial utility in the primary setting -- Bridging the gap between translational research and clinical application -- Neoadjuvant chemotherapy: early response as a guide for further treatment: clinical, radiological, and biological -- | ||
| 500 | |a Intermediate endpoints of primary systemic therapy in breast cancer patients -- International expert consensus on primary systemic therapy in the management of early breast cancer: highlights of the Fourth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2010) | ||
| 520 | |a "To clarify the role and setting for P[rimary] S[ystemic] T[herapy], during the Fourth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer held from the 26th to 28th of September 2010 in Cremona (Italy), a faculty comprising experts in the areas of medical oncology, breast surgery, molecular biology, pathology, radiodiagnostics, and radiotherapy provided an overview of recent available data from the most relevant studies and prospective clinical trials of PST in patients with operable breast cancer. At the conclusion of the congress and in the discussion, the panel of experts formulated a declaration of consensus regarding some key issues on the use of PST either in routine practice or clinical research." | ||
| 650 | 4 | |a Antineoplastic Combined Chemotherapy Protocols / therapeutic use / Congresses | |
| 650 | 4 | |a Breast Neoplasms / drug therapy / Congresses | |
| 650 | 4 | |a Breast Neoplasms / surgery / Congresses | |
| 650 | 4 | |a Neoadjuvant Therapy / Congresses | |
| 650 | 4 | |a Randomized Control Trials as Topic / Congresses | |
| 650 | 4 | |a Treatment Outcome / Congresses | |
| 655 | 7 | |0 (DE-588)1071861417 |a Konferenzschrift |2 gnd-content | |
| 830 | 0 | |a Journal of the National Cancer Institute |v Monographs ; 43 |w (DE-604)BV006157278 |9 43 | |
| 856 | 4 | 2 | |m HBZ Datenaustausch |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=024568578&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-024568578 | ||
Datensatz im Suchindex
| _version_ | 1804148598888202240 |
|---|---|
| adam_text | Titel: 4th International Consensus Conference: Primary Systemic Treatment in the Management of Operable Bre
Autor: International Consensus Conference: Primary Systemic Treatment in the Management of Operable Breast
Jahr: 2011
4th International Consensus Conference: Primary 201 1
Systemic Treatment in the Management of Number 43
Operable Breast Cancer: Toward the Rapid
Assessment of Therapy Efficacy
Contents
The Treatment of Individual Patients Is More Than a Trial, A. Bottini, A. Berruti, D. Generali, and L. Dogliotti 53
Strategies to Translate Preclinical Information to Breast Cancer Patient Benefit, M.G. Daidone, l l. Zaffaroni, and V. Cappelletti 55
The Value of Genomic Analysis of Breast Cancer in Drug Development, B. Szekely and L Pusztai 60
Biomarkers Predicting Clinical Benefit: Facts or Fiction? V. Guarneri, E. Barbieri, and P.F. Conte 63
Molecular Oncology and the Neoadjuvant Setting: the Perfect Blend for Treatment Personalization and Clinical Trial Design, 67
D. Generali, A. Berruti, C. Foroni, L. Bazzola, D. Andreis, G. Allevi, A. Bersiga, L Dogliotti, S.B. Fox, A!. Harris, and A. Bottini
Assessing Early Therapeutic Response to Bevacizumab in Primary Breast Cancer Using Magnetic Resonance Imaging and 71
Gene Expression Profiles, S. Mehta, N.P. Hughes, FM Buffa, S.P. Li, R.F. Adams, A. Adwani, N.J. Taylor, N.C. Levitt, A.R. Padhani,
A.Makris, and A!. Harris
Tissue and Soluble Biomarkers in Breast Cancer and Their Applications: Ready to Use? M. Danova, S. Delfanti, M. Manzoni, and S. Mariucci 75
kConFab: A Familial Breast Cancer Consortium Facilitating Research and Translational Oncology, H. Thorne, G. Mitchell, and S. Fox 79
The HER2 World: Better Treatment Selection for Better Outcome, E. Tagliabue, M. Campiglio, SM. Pupa, A. Balsari, and S. Menard 82
The Pathologic Complete Response Open Question in Primary Therapy, C. Marchio and A. Sapino 86
Surrogate Markers for Targeted Therapy-Based Treatment Activity and Efficacy, G. Bianchini and L. Gianni 91
Mechanisms of Resistance to HER2 Target Therapy, G. Tortora 95
Predictive Immunohistochemical Biomarkers in the Context of Neoadjuvant Therapy for Breast Cancer, D. Generali, W.F. Symmans, 99
A. Berruti, and S.B. Fox
Dynamic Contrast-Enhanced Magnetic Resonance Imaging and Blood Oxygenation Level-Dependent Magnetic Resonance Imaging 103
for the Assessment of Changes in Tumor Biology With Treatment, S.P. Li, AR. Padhani, and A. Makris
The Triple-Negative Subtype: New Ideas for the Poorest Prognosis Breast Cancer, G. Curigliano and A. Goldhirsch 108
Positron Emission Tomography and Neoadjuvant Therapy of Breast Cancer, A. Cochet, D. Generali, S.B. Fox, F. Ferrozzi, and R.J. Hicks 111
Neoadjuvant Chemotherapy and Targeted Therapies: a Promising Strategy, 0. Metzger-Filho and E. de Azambuja 116
Endocrine Therapy, New Biologicals, and New Study Designs for Presurgical Studies in Breast Cancer, M. Oowsett, I. Smith, 120
J. Robertson, L. Robison, I. Pinhel, L. Johnson, J. Salter, A. Dunbier, H. Anderson, Z. Ghazoui, T. Skene, A. Evans, R. A Hern, A. Iskender,
M.Wilcox, and J. Bliss
Gene Profiling Assay and Application: The Predictive Role in Primary Therapy, D. Fumagalli, C. Desmedt, M. Ignatiadis, S. Loi, M. Piccart, 124
and C. Sotiriou
New Omics Information for Clinical Trial Utility in the Primary Setting, G. Damia, M. Broggini, S. Marsoni, S. Venturini, and D. Generali 128
Bridging the Gap Between Translational Research and Clinical Application, W.R. Miller and A.A. Larionov 134
Neoadjuvant Chemotherapy: Early Response as a Guide for Further Treatment: Clinical, Radiological, and Biological, 138
M. Untch and G. von Minckwitz
Intermediate Endpoints of Primary Systemic Therapy in Breast Cancer Patients, A. Berruti, D. Generali, V. Bertaglia, M.P. Brizzi, T. Mele, 142
L. Dogliotti, P. Bruzzi, and A. Bottini
International Expert Consensus on Primary Systemic Therapy in the Management of Early Breast Cancer: Highlights of the Fourth 147
Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2010), A. Berruti, D. Generali,
M. Kaufmann, L. Puztai, G. Curigliano, M. Aglietta, L. Gianni, W.R. Miller, M. Untoh, C. Sotiriou, M. Daidone, P.F. Conte, D. Kennedy, G. Damia,
P. Petronini, S. Di Cosimo, P. Bruzzi, M. Dowsett, C. Desmedt, R.E. Mansel, L. Olivetti, C. Tondini, A. Sapino, P. Fenaroli, G. Tortora, H. Thorne,
F. Bertolini, F. Ferrozzi, M. Danova, E. Tagliabue, E. de Azambuja, A. Makris, M. Tampellini, G. Dontu, L. Van t Veer, Ai. Harris, S.B. Fox,
L. Dogliotti, and A. Bottini
Erratum 152
|
| any_adam_object | 1 |
| author_corporate | International Consensus Conference: Primary Systemic Treatment in the Management of Operable Breast Cancer Cremona |
| author_corporate_role | aut |
| author_facet | International Consensus Conference: Primary Systemic Treatment in the Management of Operable Breast Cancer Cremona |
| author_sort | International Consensus Conference: Primary Systemic Treatment in the Management of Operable Breast Cancer Cremona |
| building | Verbundindex |
| bvnumber | BV039720476 |
| ctrlnum | (OCoLC)759862263 (DE-599)BVBBV039720476 |
| format | Conference Proceeding Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>05198nam a2200433 cb4500</leader><controlfield tag="001">BV039720476</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20111130 </controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">111123s2011 ad|| |||| 10||| eng d</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)759862263</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV039720476</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-29</subfield><subfield code="a">DE-355</subfield><subfield code="a">DE-19</subfield><subfield code="a">DE-12</subfield></datafield><datafield tag="111" ind1="2" ind2=" "><subfield code="a">International Consensus Conference: Primary Systemic Treatment in the Management of Operable Breast Cancer</subfield><subfield code="n">4</subfield><subfield code="d">2010</subfield><subfield code="c">Cremona</subfield><subfield code="j">Verfasser</subfield><subfield code="0">(DE-588)16330833-0</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">4th International Consensus Conference: Primary Systemic Treatment in the Management of Operable Breast Cancer</subfield><subfield code="b">toward the rapid assessment of therapy efficacy</subfield><subfield code="c">sponsored by U.O. Multidisciplinare di Patologia Mammaria, Laboratorio di Oncologia Molecolare Senologica, A.O. "Istituti Ospitalieri di Cremona"</subfield></datafield><datafield tag="246" ind1="1" ind2="3"><subfield code="a">Fourth International Consensus Conference: Primary Systemic Treatment in the Management of Operable Breast Cancer</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Cary, NC</subfield><subfield code="b">Oxford Univ. Press</subfield><subfield code="c">2011</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">V S., S. 53 - 152</subfield><subfield code="b">Ill., graph. Darst</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="1" ind2=" "><subfield code="a">Journal of the National Cancer Institute : Monographs</subfield><subfield code="v">43</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Includes bibliographical references</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">The treatment of individual patients is more than a trial -- Strategies to translate preclinical information to breast cancer patient benefit -- The value of genomic analysis of breast cancer in drug development -- Biomarkers predicting clinical benefit: fact or fiction? -- Molecular oncology and the neoadjuvant setting: the perfect blend for treatment personalization and clinical trial design -- Assessing early therapeutic response to bevacizumab in primary breast cancer using magnetic resonance imaging and gene expression profiles -- Tissue and soluble biomarkers in breast cancer and their applications: ready to use? -- kConFab: a familial breast cancer consortium facilitating research and translational oncology -- The HER2 world: better treatment selection for better outcome -- The pathologic complete response open question in primary therapy -- Surrogate markers for targeted therapy-based treatment activity and efficacy -- Mechanisms of resistance to HER2 target therapy -- </subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Predictive immunohistochemical biomarkers in the context of neoadjuvant therapy for breast cancer -- Dynamic contrast-enhanced magnetic resonance imaging and blood oxygenation level-dependent magnetic resonance imaging for the assessment of changes in tumor biology with treatment -- The triple-negative subtype: new ideas for the poorest prognosis breast cancer -- Positron emission tomography and neoadjuvant therapy of breast cancer -- Neoadjuvant chemotherapy and targeted therapies: a promising strategy -- Endocrine therapy, new biologicals, and new study designs for presurgical studies in breast cancer -- Gene profiling assay and application: the predictive role in primary therapy -- New omics information for clinical trial utility in the primary setting -- Bridging the gap between translational research and clinical application -- Neoadjuvant chemotherapy: early response as a guide for further treatment: clinical, radiological, and biological -- </subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Intermediate endpoints of primary systemic therapy in breast cancer patients -- International expert consensus on primary systemic therapy in the management of early breast cancer: highlights of the Fourth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2010)</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">"To clarify the role and setting for P[rimary] S[ystemic] T[herapy], during the Fourth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer held from the 26th to 28th of September 2010 in Cremona (Italy), a faculty comprising experts in the areas of medical oncology, breast surgery, molecular biology, pathology, radiodiagnostics, and radiotherapy provided an overview of recent available data from the most relevant studies and prospective clinical trials of PST in patients with operable breast cancer. At the conclusion of the congress and in the discussion, the panel of experts formulated a declaration of consensus regarding some key issues on the use of PST either in routine practice or clinical research."</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Antineoplastic Combined Chemotherapy Protocols / therapeutic use / Congresses</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Breast Neoplasms / drug therapy / Congresses</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Breast Neoplasms / surgery / Congresses</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Neoadjuvant Therapy / Congresses</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Randomized Control Trials as Topic / Congresses</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Treatment Outcome / Congresses</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="0">(DE-588)1071861417</subfield><subfield code="a">Konferenzschrift</subfield><subfield code="2">gnd-content</subfield></datafield><datafield tag="830" ind1=" " ind2="0"><subfield code="a">Journal of the National Cancer Institute</subfield><subfield code="v">Monographs ; 43</subfield><subfield code="w">(DE-604)BV006157278</subfield><subfield code="9">43</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">HBZ Datenaustausch</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=024568578&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-024568578</subfield></datafield></record></collection> |
| genre | (DE-588)1071861417 Konferenzschrift gnd-content |
| genre_facet | Konferenzschrift |
| id | DE-604.BV039720476 |
| illustrated | Illustrated |
| indexdate | 2024-07-10T00:09:41Z |
| institution | BVB |
| institution_GND | (DE-588)16330833-0 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-024568578 |
| oclc_num | 759862263 |
| open_access_boolean | |
| owner | DE-29 DE-355 DE-BY-UBR DE-19 DE-BY-UBM DE-12 |
| owner_facet | DE-29 DE-355 DE-BY-UBR DE-19 DE-BY-UBM DE-12 |
| physical | V S., S. 53 - 152 Ill., graph. Darst |
| publishDate | 2011 |
| publishDateSearch | 2011 |
| publishDateSort | 2011 |
| publisher | Oxford Univ. Press |
| record_format | marc |
| series | Journal of the National Cancer Institute |
| series2 | Journal of the National Cancer Institute : Monographs |
| spelling | International Consensus Conference: Primary Systemic Treatment in the Management of Operable Breast Cancer 4 2010 Cremona Verfasser (DE-588)16330833-0 aut 4th International Consensus Conference: Primary Systemic Treatment in the Management of Operable Breast Cancer toward the rapid assessment of therapy efficacy sponsored by U.O. Multidisciplinare di Patologia Mammaria, Laboratorio di Oncologia Molecolare Senologica, A.O. "Istituti Ospitalieri di Cremona" Fourth International Consensus Conference: Primary Systemic Treatment in the Management of Operable Breast Cancer Cary, NC Oxford Univ. Press 2011 V S., S. 53 - 152 Ill., graph. Darst txt rdacontent n rdamedia nc rdacarrier Journal of the National Cancer Institute : Monographs 43 Includes bibliographical references The treatment of individual patients is more than a trial -- Strategies to translate preclinical information to breast cancer patient benefit -- The value of genomic analysis of breast cancer in drug development -- Biomarkers predicting clinical benefit: fact or fiction? -- Molecular oncology and the neoadjuvant setting: the perfect blend for treatment personalization and clinical trial design -- Assessing early therapeutic response to bevacizumab in primary breast cancer using magnetic resonance imaging and gene expression profiles -- Tissue and soluble biomarkers in breast cancer and their applications: ready to use? -- kConFab: a familial breast cancer consortium facilitating research and translational oncology -- The HER2 world: better treatment selection for better outcome -- The pathologic complete response open question in primary therapy -- Surrogate markers for targeted therapy-based treatment activity and efficacy -- Mechanisms of resistance to HER2 target therapy -- Predictive immunohistochemical biomarkers in the context of neoadjuvant therapy for breast cancer -- Dynamic contrast-enhanced magnetic resonance imaging and blood oxygenation level-dependent magnetic resonance imaging for the assessment of changes in tumor biology with treatment -- The triple-negative subtype: new ideas for the poorest prognosis breast cancer -- Positron emission tomography and neoadjuvant therapy of breast cancer -- Neoadjuvant chemotherapy and targeted therapies: a promising strategy -- Endocrine therapy, new biologicals, and new study designs for presurgical studies in breast cancer -- Gene profiling assay and application: the predictive role in primary therapy -- New omics information for clinical trial utility in the primary setting -- Bridging the gap between translational research and clinical application -- Neoadjuvant chemotherapy: early response as a guide for further treatment: clinical, radiological, and biological -- Intermediate endpoints of primary systemic therapy in breast cancer patients -- International expert consensus on primary systemic therapy in the management of early breast cancer: highlights of the Fourth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2010) "To clarify the role and setting for P[rimary] S[ystemic] T[herapy], during the Fourth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer held from the 26th to 28th of September 2010 in Cremona (Italy), a faculty comprising experts in the areas of medical oncology, breast surgery, molecular biology, pathology, radiodiagnostics, and radiotherapy provided an overview of recent available data from the most relevant studies and prospective clinical trials of PST in patients with operable breast cancer. At the conclusion of the congress and in the discussion, the panel of experts formulated a declaration of consensus regarding some key issues on the use of PST either in routine practice or clinical research." Antineoplastic Combined Chemotherapy Protocols / therapeutic use / Congresses Breast Neoplasms / drug therapy / Congresses Breast Neoplasms / surgery / Congresses Neoadjuvant Therapy / Congresses Randomized Control Trials as Topic / Congresses Treatment Outcome / Congresses (DE-588)1071861417 Konferenzschrift gnd-content Journal of the National Cancer Institute Monographs ; 43 (DE-604)BV006157278 43 HBZ Datenaustausch application/pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=024568578&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA Inhaltsverzeichnis |
| spellingShingle | 4th International Consensus Conference: Primary Systemic Treatment in the Management of Operable Breast Cancer toward the rapid assessment of therapy efficacy Journal of the National Cancer Institute Antineoplastic Combined Chemotherapy Protocols / therapeutic use / Congresses Breast Neoplasms / drug therapy / Congresses Breast Neoplasms / surgery / Congresses Neoadjuvant Therapy / Congresses Randomized Control Trials as Topic / Congresses Treatment Outcome / Congresses |
| subject_GND | (DE-588)1071861417 |
| title | 4th International Consensus Conference: Primary Systemic Treatment in the Management of Operable Breast Cancer toward the rapid assessment of therapy efficacy |
| title_alt | Fourth International Consensus Conference: Primary Systemic Treatment in the Management of Operable Breast Cancer |
| title_auth | 4th International Consensus Conference: Primary Systemic Treatment in the Management of Operable Breast Cancer toward the rapid assessment of therapy efficacy |
| title_exact_search | 4th International Consensus Conference: Primary Systemic Treatment in the Management of Operable Breast Cancer toward the rapid assessment of therapy efficacy |
| title_full | 4th International Consensus Conference: Primary Systemic Treatment in the Management of Operable Breast Cancer toward the rapid assessment of therapy efficacy sponsored by U.O. Multidisciplinare di Patologia Mammaria, Laboratorio di Oncologia Molecolare Senologica, A.O. "Istituti Ospitalieri di Cremona" |
| title_fullStr | 4th International Consensus Conference: Primary Systemic Treatment in the Management of Operable Breast Cancer toward the rapid assessment of therapy efficacy sponsored by U.O. Multidisciplinare di Patologia Mammaria, Laboratorio di Oncologia Molecolare Senologica, A.O. "Istituti Ospitalieri di Cremona" |
| title_full_unstemmed | 4th International Consensus Conference: Primary Systemic Treatment in the Management of Operable Breast Cancer toward the rapid assessment of therapy efficacy sponsored by U.O. Multidisciplinare di Patologia Mammaria, Laboratorio di Oncologia Molecolare Senologica, A.O. "Istituti Ospitalieri di Cremona" |
| title_short | 4th International Consensus Conference: Primary Systemic Treatment in the Management of Operable Breast Cancer |
| title_sort | 4th international consensus conference primary systemic treatment in the management of operable breast cancer toward the rapid assessment of therapy efficacy |
| title_sub | toward the rapid assessment of therapy efficacy |
| topic | Antineoplastic Combined Chemotherapy Protocols / therapeutic use / Congresses Breast Neoplasms / drug therapy / Congresses Breast Neoplasms / surgery / Congresses Neoadjuvant Therapy / Congresses Randomized Control Trials as Topic / Congresses Treatment Outcome / Congresses |
| topic_facet | Antineoplastic Combined Chemotherapy Protocols / therapeutic use / Congresses Breast Neoplasms / drug therapy / Congresses Breast Neoplasms / surgery / Congresses Neoadjuvant Therapy / Congresses Randomized Control Trials as Topic / Congresses Treatment Outcome / Congresses Konferenzschrift |
| url | http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=024568578&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |
| volume_link | (DE-604)BV006157278 |
| work_keys_str_mv | AT internationalconsensusconferenceprimarysystemictreatmentinthemanagementofoperablebreastcancercremona 4thinternationalconsensusconferenceprimarysystemictreatmentinthemanagementofoperablebreastcancertowardtherapidassessmentoftherapyefficacy AT internationalconsensusconferenceprimarysystemictreatmentinthemanagementofoperablebreastcancercremona fourthinternationalconsensusconferenceprimarysystemictreatmentinthemanagementofoperablebreastcancer |